Who invests in bioinformatics startups?
Bioinformatics sits where biology meets software, and the investor list reflects that. Of the 950+ bioinformatics investors in Angel Match, nearly four in five carry a venture capital tag and more than half are tagged as angel investors. Those groups overlap, because one person can invest through a fund and write personal checks too. More than a third also carry a private equity tag, and smaller groups include micro VCs, accelerators and corporate venture investors.
One thing to know before you start emailing: almost nobody on this list invests in bioinformatics alone. The investors we sampled each carry dozens of other market tags, and broad ones like health care show up again and again. So you're rarely pitching a bioinformatics specialist. You're pitching a life science or software investor who has an interest in companies like yours. That changes how you write your email. Don't assume they know your sub-field. Explain what the software does and who pays for it in plain words.
If your company leans toward the lab side, the genomics investors and biotechnology investors lists are worth a look too. Expect some overlap between them, so cross-check before you email the same person twice.
Where bioinformatics investors are based
About six in ten bioinformatics investors on Angel Match are in the United States. California leads with 150+, close to one in five of the whole list, and San Francisco alone accounts for 100+. Massachusetts comes next with 80+, most of them in Boston. New York follows with 60+, nearly all in New York City.
That map won't surprise anyone who works in the field. The investors who understand biological data sit close to the labs, hospitals and biotech companies that produce it. If you're based in one of those hubs, say so early in your email. If you're not, expect to travel for the meetings that matter.
Outside the US, the United Kingdom is the biggest group with 50+, followed by Canada. Israel, Belgium and Switzerland each have 20+. Two details are worth your attention. First, Israel and Belgium both have more bioinformatics investors on the list than Germany does, even though Germany is a far bigger economy. So don't size your target list by country size. A small country with a strong life science scene can give you more relevant names than a big one. Second, Chicago has about as many bioinformatics investors as London, which makes the Midwest worth a line in your spreadsheet.
Most of these investors come in after pre-seed
The stage mix is the most useful thing on this page if you're raising early. More than four in ten bioinformatics investors are tagged early stage venture, which is more than twice the number tagged seed. Pre-seed is thin: 40+ investors, fewer than one in twenty. Series A and Series B specialists are small groups of about the same size.
What does that mean for you? If you have a working product and some proof it holds up on real data, you're in the widest part of the funnel. If you're pre-product, the list of people who back companies at your stage is short. You'll need other money to get to the point where the bigger group pays attention.
For many bioinformatics founders, that other money is a grant. In the US, NIH's small business programs (SBIR and STTR) support early research and development without taking equity, and NIH confirmed in April 2026 that they were reauthorized for the next five years. A grant won't replace a round, but it can pay for the validation work that makes your seed pitch much stronger.
Angels are the other route. Angel checks usually run $25,000 to $500,000, which is enough to fund a pilot or a first hire. Venture checks start much higher, from $2 million to $100 million or more, so they only make sense once you've got something to scale. Either way, plan your cash carefully, because validation in this field often takes longer than founders expect. A runway calculator will show you how many months you really have before you need the next check.
Why investors care about bioinformatics right now
Reading DNA got cheap. Making sense of it didn't. According to the National Human Genome Research Institute, generating a high-quality draft human genome cost about $14 million in 2006. By late 2015 that figure had fallen below $1,500. The same fact sheet notes that those cost figures typically leave out steps like aligning the sequence to a reference genome, calling variants and annotation. That's the analysis work, and it's what bioinformatics companies sell.
So the pile of data keeps growing and the bottleneck has moved to software. Investors have noticed, mostly through the AI lens. Nobody publishes a funding tally for bioinformatics on its own, so the closest proxy is AI-focused biotech. Crunchbase News reported in late August that more than $6 billion had gone to AI-focused biotech startups so far in 2026, led by a $2.1 billion Series B for Isomorphic Labs, a London company that designs drugs with AI.
More money in the sector doesn't mean raising got easier for you, though. Add up the three biggest rounds in that report and you get roughly $3.3 billion, so a small number of companies took a big share. The better news is in the same report: seed and early-stage rounds made up more than half of all biotech startup investment this year. That lines up with what the stage data on this page shows. The money in this field is concentrated early, just not at the very first check.
What bioinformatics investors want to see
Because most people on this list are generalist life science or software investors, your pitch has to answer a few questions fast.
- Are you a tool, a platform or a drug company? A company that sells analysis software to labs gets judged on revenue and contracts. A company that uses its own software to find drug candidates gets judged on scientific milestones. Investors price these very differently, so say which one you are in the first two lines of your email.
- Where does your data come from? An algorithm trained on public datasets is easy to copy. Investors want to know what data you have that others can't get, who owns it and whether you're allowed to use it commercially. If patient data is involved, be ready to explain consent and privacy.
- Has it been tested outside your own team? A benchmark you ran yourself is a start. A result confirmed in a wet lab, a peer-reviewed paper or a paid pilot with a research group is much stronger.
- Who pays, and how long does it take? Academic labs love new tools but tend to buy slowly and in small amounts. Pharma companies have bigger budgets and longer security and procurement reviews. Show that you know your sales cycle and have the cash to survive it.
- Is it for research use or clinical use? Software that informs patient care faces a regulatory path that research tools don't. Tell investors which side you're on, and what it'll take to cross over if that's the plan.
Expect diligence to go deep on the second and third points. Investors will ask for data licenses, validation results and customer contracts, so it helps to have them organized in a data room before the first serious call.
Building your bioinformatics investor list
A good target list for a bioinformatics raise is shorter than you'd think. Start with stage, because that's where most mismatches happen. Pick the investors whose stage tag fits where you are today, not where you hope to be in a year. Then filter by place, since being close to an investor makes lab visits and in-person meetings with your scientific team much easier. Last, read each investor's past investments and keep the ones who've backed a company with a business model like yours, whether that's software sales or drug discovery.
With 950+ bioinformatics investors and most of them clustered at the early venture stage in a few US hubs, the work is in cutting the list down, not building it up. The full investor database lets you stack the bioinformatics filter with stage and location, so you end up with a short list of people who are actually worth an email. Start with the ones closest to your stage and your city, and work outward from there.
Genomics investors
